Anzeige
Mehr »
Freitag, 29.08.2025 - Börsentäglich über 12.000 News

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2AC4K | ISIN: US28106W1036 | Ticker-Symbol: 8EM
Tradegate
27.08.25 | 14:37
2,349 Euro
+3,75 % +0,085
1-Jahres-Chart
EDITAS MEDICINE INC Chart 1 Jahr
5-Tage-Chart
EDITAS MEDICINE INC 5-Tage-Chart
RealtimeGeldBriefZeit
2,2382,33709:00
2,2382,33707:56

Aktuelle News zur EDITAS MEDICINE Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
15.08.H.C. Wainwright raises Editas Medicine stock price target to $5 on pipeline progress3
15.08.Why Editas Medicine Stock Was Skyrocketing This Week2
13.08.Editas Medicine Shares Soar 35% On Synthetic Biology Market Growth Outlook20
12.08.Editas Medicine, Inc.: Editas Medicine Announces Second Quarter 2025 Results and Business Updates829Company to select lead development candidate in September; on track to file IND by mid-2026 and achieve human proof-of-concept by year-end 2026 First IND/CTA accepted for CD19 HD Allo CAR T program...
► Artikel lesen
28.06.Wall Street Expects Editas Medicine to Soar 53%. Is It Time to Buy Now?61
17.06.Editas Medicine Is Great. Here's Why You Shouldn't Buy It.12
12.06.Editas Medicine, Inc. - 8-K, Current Report16
12.06.Editas Medicine, Inc.: Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology ...337Achieved 58% mean editing at five months after a single dose using high efficiency HSC delivery, demonstrating therapeutically relevant editing levels using a clinically validated strategy. Achievement...
► Artikel lesen
EDITAS MEDICINE Aktie jetzt für 0€ handeln
02.06.Editas Medicine ändert Aktienplan und erhöht genehmigte Aktien18
02.06.Editas Medicine, Inc. - 8-K, Current Report1
28.05.Editas Medicine, Cassava Sciences among healthcare stocks to join Russell Microcap; MNKD, OCGN to exit58
16.05.Editas Medicine: A Cautionary Tale for Investors7
14.05.Editas Medicine, Inc.: Editas Medicine to Present in vivo HSC Delivery, Editing, and Biodistribution Data at the European Hematology Association 2025 Congress in June2
14.05.Editas Medicine, Inc.: Editas Medicine Reports New In Vivo Data Highlighting the Potential of Editas' Gene Upregulation Strategy in HSCs at the American Society of Gene and Cell Therapy Annual Meeting244Data demonstrate therapeutically relevant editing levels using a clinically validated strategy, supporting its development as a novel, in vivo approach to treating sickle cell disease and beta thalassemia...
► Artikel lesen
13.05.Editas Medicine meldet Durchbruch bei der Behandlung von Lebererkrankungen18
13.05.Editas Medicine reports breakthrough in liver disease treatment3
13.05.Editas Medicine, Inc.: Editas Medicine Reports New In Vivo Proof of Concept Data in an Undisclosed Liver Target at the American Society of Gene and Cell Therapy Annual Meeting196In vivo CRISPR Editing Results in Functional Upregulation of a Liver Target Protein and Meaningful Reduction of Disease-Associated Biomarker in Mice CAMBRIDGE, Mass., May 13, 2025 (GLOBE NEWSWIRE)...
► Artikel lesen
13.05.Editas Medicine stock target cut to $4 at Evercore ISI3
12.05.Editas Medicine, Inc. - 10-Q, Quarterly Report2
12.05.Editas Medicine, Inc.: Editas Medicine Announces First Quarter 2025 Results and Business Updates498Company to share in vivo preclinical data demonstrating the successful use of targeted lipid nanoparticles to deliver HBG1/2 promoter editing cargo to hematopoietic stem and progenitor cells (HSPCs)...
► Artikel lesen
Weiter >>
42 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1